| 80.95 0.19 (0.24%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 107.91 | 1-year : | 122.63 |
| Resists | First : | 92.39 | Second : | 105 |
| Pivot price | 81.66  |
|||
| Supports | First : | 72 | Second : | 59.9 |
| MAs | MA(5) : | 82.18 |
MA(20) : | 83.77 |
| MA(100) : | 55.7 |
MA(250) : | 42.17 |
|
| MACD | MACD : | 1.3 |
Signal : | 2.5 |
| %K %D | K(14,3) : | 50.3 |
D(3) : | 46.2 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 105 | Low : | 16.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MNPR ] has closed above bottom band by 42.9%. Bollinger Bands are 53.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 84.06 - 84.61 | 84.61 - 85.12 |
| Low: | 76.54 - 77.21 | 77.21 - 77.83 |
| Close: | 79.88 - 80.97 | 80.97 - 81.96 |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Sun, 09 Nov 2025
Monopar Therapeutics (MNPR) Unveils Promising Phase 2 Study Resu - GuruFocus
Sun, 09 Nov 2025
Monopar Therapeutics Presents Positive Phase 2 Study Results of ALXN1840 for Wilson Disease at AASLD 2025 - Quiver Quantitative
Tue, 04 Nov 2025
Monopar Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview - TradingView
Wed, 29 Oct 2025
Monopar Therapeutics (MNPR) Price Target Increased by 14.64% to 113.81 - Nasdaq
Tue, 21 Oct 2025
Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 24 (%) |
| Held by Institutions | 48.3 (%) |
| Shares Short | 162 (K) |
| Shares Short P.Month | 147 (K) |
| EPS | -3.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.52 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.2 % |
| Return on Equity (ttm) | -59.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -21.09 |
| PEG Ratio | 0 |
| Price to Book value | 9.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -50.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|